NCT06964113进行中（未招募）4 期
A Multi-center, Open-Label, Single-Arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib 200 mg in Korean Patients With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 94
- 试验地点
- 47
- 主要终点
- Percentage of Participants Achieving Clinical Remission at Week 10 or 22
研究概览
简要总结
The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult participants aged 19 to 64 years at the time of written consent
- •Participants must meet both of the following conditions:
- •i) Diagnosed with moderately to severely active ulcerative colitis as determined by the Mayo Clinic Score with endoscopy occurring during screening; total score must be between 6 and 12, inclusive and endoscopy sub-score greater than or equal to (>=) 2 (However, if there are results of an endoscopy performed within two (2) months of the screening visit, and if NHI evaluation can be performed using the stored specimens obtained from that endoscopy, it can replace screening endoscopy.) ii) Have had an inadequate response to, lost response to, or were intolerant to either conventional therapy (corticosteroids, immunosuppressants, etc.) or a biologic agent based on the investigator's judgement at the screening visit.
- •Participant who is considered reliable by the investigator regarding provision of information, and is willing to comply with the study protocol procedures
排除标准
- •Participants with hypersensitivity to the active substance or to any of the excipients listed in the approved label of filgotinib
- •Participants with active infections, including serious infections (example [e.g.], sepsis) or local infections
- •Participants with active tuberculosis (TB). For participants with latent tuberculosis, domestic standard anti-tuberculosis therapy must be initiated at least 3 weeks prior to the first administration of the study drug (Visit 2, Day 1).
- •Participants with severe hepatic impairment (Child-Pugh C)
- •Participants with moderate or greater renal impairment (Creatinine Clearance [CrCl] less than (<) 60 milliliter per minute [mL/min])
- •Participants who meet any of the following laboratory values:
- •Absolute neutrophil count (ANC) less than (<) 1*10^9 cells per liter (/L)
- •Absolute lymphocyte count (ALC) <0.5*10^9 cells/L
- •Hemoglobin level <8 grams per deciliter (g/dL)
- •Hemoglobin level <8 g/dL
- •Female participants who are pregnant or breastfeeding at Visit
- •Even if a pregnancy test result at Visit 1 was negative, a separate evaluation is required at Visit 2 if the first dose of the study drug was administered more than 72 hours after the pregnancy test.
- •Female participants of childbearing potential who do not agree to use one of the following highly effective methods of contraception from 4 weeks prior to Visit 1 until 4 weeks after the last dose of study drug:
- •Complete abstinence (if this is the preferred and usual lifestyle of the participants)
- •Intrauterine device or hormone-containing intrauterine system (IUS)
- •Contraceptive implant
- •Oral contraceptives (participants must be on the same oral contraceptive at a stable dose for at least 4 weeks prior to the administration of the study drug, during the study and for 4 weeks after discontinuation of the study drug)
- •Partner has had a vasectomy and is confirmed to be azoospermia If a highly effective method of contraception is not appropriate or acceptable for the participants, the participants must agree to use a medically acceptable method of contraception, that is (i.e.), double barrier method of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide.
- •Note: All women will be considered to be of childbearing potential unless they are postmenopausal (at least 12 consecutive months of amenorrhea with no other known or suspected cause) or surgically sterile (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all surgically performed, at least 1 month prior to the administration of the study drug).
- •Participants with hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
- •Participants with a history of prior treatment with Janus kinase (JAK) inhibitor
- •Participants currently participating in other clinical study or participants who used other investigational product/medical device within 4 weeks of the screening visit
- •Participants deemed inappropriate to participate in this study at the investigator's discretion.
研究组 & 干预措施
Filgotinib Maleate 200 milligram per day (mg/day)
Experimental
干预措施: Filgotinib Maleate (Drug)
结局指标
主要结局
Percentage of Participants Achieving Clinical Remission at Week 10 or 22
时间窗: At Week 10 or 22
次要结局
- Percentage of Participants Achieving Clinical Remission at Weeks 10, 22 and 58(At Weeks 10, 22 and 58)
- Percentage of Clinical Responders at Week 10 and 22(At Week 10 and 22)
- Percentage of Participants Achieving Sustained Clinical Remission at Week 58(At Week 58)
- Percentage of Participants Achieving 6-month Corticosteroid-free Clinical Remission at Week 58(At Week 58)
- Number of Participants With Adverse Events (AEs)(Up to 62 weeks)
- Number of Participants With Clinically Significant Abnormal Laboratory Tests(Up to 62 weeks)
- Number of Participants With Clinically Significant Abnormal Vital Signs(Up to 62 weeks)
- Number of Participants With Clinically Significant Abnormal Weight(Up to 62 weeks)
- Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Measurements(Up to 62 weeks)
- Duration of Filgotinib Exposure(Up to 58 weeks)
- Percentage of Participants Who Complied to Treatment(Up to 58 weeks)
- Percentage of Participants Achieving Mayo Clinic Score (MCS) Remission at Weeks 10, 22, and 58(At Weeks 10, 22, and 58)
- Percentage of Participants Achieving Endoscopic Subscore of 0 at Weeks 10, 22, and 58(At Weeks 10, 22, and 58)
- Percentage of Participants Achieving Nancy Histologic Index (NHI) Histologic Remission at Weeks 10, 22, and 58(At Weeks 10, 22, and 58)
- Percentage of Participants Achieving MCS Remission (Alternative Definition) at Weeks 10, 22, and 58(At Weeks 10, 22, and 58)
研究者
研究点 (47)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisNCT02914522Gilead Sciences1,351
已完成
3 期
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseCrohn's DiseaseNCT02914561Galapagos NV1,372
已完成
2 期
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)Small Bowel Crohn's DiseaseNCT03046056Gilead Sciences78
终止
3 期
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD TherapyPsoriatic ArthritisNCT04115748Gilead Sciences67
终止
2 期
Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious UveitisNoninfectious UveitisNCT03207815Gilead Sciences74